Cytotoxic T Cell Induction against Human Malignant Melanoma Cells Using HLA-A24-restricted Melanoma Peptide Cocktail

Anticancer Research

Volumn 24, Issue 2 B, 2004, Pages 571-577

  Akiyama, Yasuto ^a,e   Maruyama, Kouji ^a   Nara, Noriko ^a   Mochizuki, Tohru ^b   Yamamoto, Akifumi ^c   Yamazaki, Naoya ^c   Kawashima, Ichiro ^d   Nukaya, Ikuei ^d   Takesako, Kazutoh ^d   Yamaguchi, Ken ^e  

^a NATIONAL CANCER CENTER RESEARCH INSTITUTE   (Japan)

^b UNIVERSITY OF SHIZUOKA   (Japan)

^c NATIONAL CANCER CENTER HOSPITAL   (Japan)

^d TAKARA BIO INC   (Japan)

^e SHIZUOKA CANCER CENTER   (Japan)

Author keywords

CTL epitope; Cytotoxic T cell (CTL); HLA A*2402 restricted peptide cocktail; HLA A24 motif; Metastatic melanoma

Indexed keywords

ALANYLPHENYLALANYLLYSYLPROLYLTRYPTOPHYLHISTIDYLARGINYLLEUCYLPHENYLALANINE; ASPARAGINYLTYROSYLLYSYLHISTIDYLCYSTEINYLPHENYLALANYLPROLYLGLUTAMYLISOLEUCINE; EPITOPE; GAMMA INTERFERON; GLUTAMYLTYROSYLLEUCYLGLUTAMINYLLEUCYLVALYLPHENYLALANYLGLYCYLISOLEUCINE; GLYCOPROTEIN GP 100; HLA A24 ANTIGEN; HLA A2402 ANTIGEN; IMMUNOSUPPRESSIVE AGENT; ISOLEUCYLMETHIONYLPROLYLLYSYLALANYLGLYCYLLEUCYLLEUCYLISOLEUCINE; MELANOMA ANTIGEN 1; MELANOMA ANTIGEN 2; MELANOMA ANTIGEN 3; MELANOMA ASSOCIATED PEPTIDE; MONOPHENOL MONOOXYGENASE; SYNTHETIC PEPTIDE; UNCLASSIFIED DRUG; VALYLTRYPTOPHYLLYSYLTHREONYLTRYPTOPHYLGLYCYLGLUTAMINYLTYROSYLTRYPTOPHAN;

ALLELE; ARTICLE; CANCER IMMUNOTHERAPY; CAUCASIAN; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; DENDRITIC CELL; DRUG EFFICACY; HLA SYSTEM; HUMAN; HUMAN CELL; MELANOMA; PERIPHERAL LYMPHOCYTE; PRIORITY JOURNAL;

ANTIGENS, NEOPLASM; CANCER VACCINES; DENDRITIC CELLS; HLA-A ANTIGENS; HUMANS; INTERFERON TYPE II; LYMPHOCYTE ACTIVATION; MELANOMA; MEMBRANE GLYCOPROTEINS; MONOPHENOL MONOOXYGENASE; NEOPLASM PROTEINS; PEPTIDE FRAGMENTS; T-LYMPHOCYTES, CYTOTOXIC;

EID: 2442447391     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (24)

1. Renkvist N, Castelli C, Robbins PF and Parmiani G: A listing of human tumor antigens recognized by T cells. Cancer Immunol Immunother 50: 3-15, 2001.
2. Kawakami Y, Eliyasu S, Sakaguchi K, Robbins PF, Rivoltini L, Yannelli JR, Appella E and Rosenberg SA: Identification of the immunodominant peptides of the MART-1 human melanoma antigen recognized by the majority of HLA-A2-restrieted tumor infiltrating lymphocytes. J Exp Med 180: 347-52, 1994.
3. Bakker AB, Marland G, de Boer AJ, Huijbens RJ, Danen HJ, Adema GJ and Figdor CG: Generation of antimelanoma cytotoxic T lymphocytes from healthy donors after presentation of melanoma-associated antigen-derived epitopes by dendritic cells in vitro. Cancer Res 55: 5330-4, 1995.
4. Wölfel T, van Pel A, Brichard V, Schneider J, Seliger B, Büschenfelde KH and Boon T: Two tyrosinase nonapeptides recognized on HLA-A2 melanomas by autologous cytolytic T lymphocytes. Eur J Immunol 24: 759-64, 1994.
5. Kawashima I, Huddon SJ, Ysai V, Southwood S, Takesako K, Appella A and Celis E: The multi-epitope approach for immunotherapy for cancer: identification of several CTL epitopes from various tumor-associated antigens expressed on solid epithelial tumors. Hum Immunol 50: 1-14, 1998.
6. Van der Bruggen P, Bastin J, Gajewski T, Coulie PG, Boel P, de Smet C, Traversari C, Townsend A and Boon T: A peptide encoded by human gene MAGE-3 and presented by HLA-A2 induces cytolytic T lymphocytes that recognize tumor cells expressing MAGE-3. Eur J Immunol 24: 3038-43, 1994.
7. Thurner B, Haendle I, Roder C, Dieckmann D, Keikavoussi P, Jonuleit H, Bender A, Maczek C, Schreiner D, von den Driesch P, Brocker EB, Steinman RM, Enk A, Kampgen E and Schuler G: Vaccination with mage-3A1 peptide-pulsed mature, monocyte-derived dendritic cells expands specific cytotoxic T cells and induces regression of some metastases in advanced stage IV melanoma. J Exp Med 6: 1669-78, 1999.
8. Panelli MC, Wunderlich J, Jeffries J, Wang E, Mixon A, Rosenberg SA and Marincola FM: Phase I study in patients with metastatic melanoma of immunization with dendritic cells presenting epitopes derived from the melanoma-associated antigens MART-1 and gp100. J Immunother 23: 487-98, 2000.
9. Lau R, Wang F, Jeffery G, Marty V, Kuniyoshi J, Bade E Ryback ME and Weber J: Phase I trial of intravenous peptide-pulsed dendritic cells in patients with metastatic melanoma. J Immunother 24: 66-78, 2001.
10. Kang X, Kawakami Y, El-Gamil M, Wang R, Sakaguchi K, Yannelli JR, Appella E, Rosenberg SA and Robbins PF: Identification of a tyrosinase epitope recognized by HLA-A24-restricted, tumor-infiltrating lymphocytes. J Immunol 155: 1343-8, 1995.
11. Fujie T Tahara K, Tanaka F, Mori M, Takesako K and Akiyoshi T: A MAGE-1-encoded HLA-A24-binding synthetic peptide induces specific anti-tumor cytotoxic T lymphocytes. Int J Cancer 80: 169-72, 1999.
12. Tahara K, Takasako K, Sette A, Celis E, Kitano S and Akiyoshi T: Identification of a MAGE-2-encoded human leukocyte antigen-A24-binding synthetic peptide that induces specific antitumor cytotoxic T lymphocytes. Clin Cancer Res 5: 2236-41, 1999.
13. Tanaka F, Fujie T, Tahara K, Mori M, Takasako K, Sette A, Celis E and Akiyoshi T: Induction of antitumor cytotoxic T lymphocytes with a MAGE-3-encoded synthetic peptide presented by human leukocytes antigen-A24. Cancer Res 57: 4465-8, 1997.
14. Kondo A, Sidney J, Southwood S, del Guercio MF, Appella E, Sakamoto H, Celis E, Grey HM, Chesnut RW and Kubo RT: Prominent roles of secondary anchor residues in peptide binding to HLA-A24 human class I molecules. J Immunol 155: 4307-12, 1995.
15. Maruyama K, Akiyama Y, Nara-Ashizawa N, Hojo T, Cheng JY, Mizuguchi H, Hayakawa T and Yamaguchi K: Adenovirus-mediated MUC1 gene transduction into human blood-derived dendritic cells. J Immunother 24: 345-53, 2001.
16. Zendman AJ, de Wit NJ, van Kraats AA, Weidle UH, Ruiter DJ and van Muijen GN: Expression profile of genes coding for melanoma differentiation antigens and cancer/testis antigens in metastatic lesions of human cutaneous melanoma. Melanoma Res 11: 451-9, 2001.
17. + hematopoietic progenitor cells. Int J Cancer 86: 385-92, 2000.
18. Nestle FO, Alijagic S, Gilliet M, Sun Y, Grabbe S, Dummer R, Burg G and Schadendorf D: Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells. Nat Med 4: 328-32, 1998.
19. Banchereau J, Palucka AK, Dhodapkar M, Burkeholder S, Taquet N, Rolland A, Taquet S, Coquery S, Wittkowski KM, Bhardwaj N, Pineiro L, Steinman R and Fay J: Immune and clinical responses in patients with metastatic melanoma to CD34+ progenitor-derived dendritic cell vaccine. Cancer Res 61: 6451-8, 2001.
20. Smith SG, Patel PM, Porte J, Selby PJ and Jackson AM: Human dendritic cells genetically engineered to express a melanoma polyepitope DNA vaccine induce multiple cytotoxic T-cell responses. Clin Cancer Res 7: 4253-61, 2001.
21. Seo N, Hayakawa S, Takigawa M and Tokura Y: Interleukin-10 expressed at early tumour sites induces subsequent generation of CD4 (+) T-regulatory cells and systemic collapse of antitumor immunity. Immunology 103: 449-57, 2001.
22. Nemunaitis J, Fong T, Shabe P, Martineau D and Ando D: Comparison of serum interleukin-10 (IL-10) levels between normal volunteers and patients with advanced melanoma. Cancer Invest 19: 239-47, 2001.
23. Steinbrink K, Graulich E, Kubsch S, Knop J and Enk AH: CD4 (+) and CD8 (+) anergic T cells induced by interleukin-10-treated human dendritic cells display antigen-specific suppressor activity. Blood 99: 2468-76, 2002.
24. Harada M, Tatsugani K, Nomoto M and Nomoto K: Circulating immunoglobulin-bound transforming growth factor beta at a late tumour-bearing stage impairs antigen-specific responses of CD4+ T cells. Clin Exp Immunol 128: 204-12, 2002.